The diametric regulatory mechanism and outcome for TNFR2 signaling suggest that blockade of both TNFR1and TNFR2 signaling in astrocytes is required for the suppression of CNS inflammation, representing a new therapeutic strategy for CNS inflammation which is distinct from those proposed for autoimmune disease [54]. This evidence concerns the gene TNFRSF1B and autoimmune disease.